Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

121.41 +2.17 (+1.82%)
Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
News headline image
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer ↗
Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg. 
Via Benzinga
News headline image
2 Healthcare Dividend Stocks to Hold for the Long Haul ↗
Via The Motley Fool
News headline image
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday ↗
Via The Motley Fool
News headline image
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy? ↗
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
News headline image
3 Ultra-Cheap Dividend Stocks to Buy in December ↗
Via The Motley Fool
News headline image
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance ↗
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
News headline image
Merck & Co Unusual Options Activity For December 02 ↗
 
Via Benzinga
News headline image
Why NYSE:MRK provides a good dividend, while having solid fundamentals. ↗
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
News headline image
The Smartest Dividend Stocks to Buy With $3,000 Right Now ↗
They may not offer the very highest yields, but their dividends are built to last, and even grow. 
Via The Motley Fool
News headline image
The Data Shows Three Market-Jolting Forces On The Move ↗
What we saw in the inflation data, income and spending-related reports points to a couple of big moves we need to start making now. 
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
Why Is Merck Stock Trading Higher On Monday? ↗
Merck's ZENITH trial shows Winrevair significantly lowers morbidity or mortality risk in PAH patients, building on earlier Phase 3 STELLAR results. 
Via Benzinga
News headline image
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns ↗
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
News headline image
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist ↗
Via The Motley Fool
News headline image
NYSE:MRK appears to be flying under the radar despite its strong fundamentals. ↗
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients ↗
Merck's Phase 3 trial shows subcutaneous pembrolizumab is as effective as IV Keytruda for first-line NSCLC treatment, meeting key pharmacokinetic goals. 
Via Benzinga
News headline image
Not-So-Big Pharma ↗
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
News headline image
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth ↗
To gain an edge, this is what you need to know today. 
Via Benzinga
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial ↗
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy. 
Via Benzinga
News headline image
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics ↗
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
Via Investor's Business Daily
News headline image
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day? ↗
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Biotech Stocks Are Rallying: What Is Your Playbook? ↗
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
News headline image
3 Stocks Poised for a Breakout ↗
All 3 stocks are high on my watchlist. 
Via The Motley Fool
News headline image
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
News headline image
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
News headline image
2 Hot Biopharma Stocks to Buy and Hold for 5 Years ↗
If you're patient, these businesses have a lot of promising projects in the works. 
Via The Motley Fool
News headline image
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows. ↗
These stocks have seen better days but investors shouldn't count them out in the long run. 
Via The Motley Fool
News headline image
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
 
Via Benzinga
News headline image
Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom ↗
Broadcom expanded its multi-year partnership with Telia Company to advance telecom and cloud infrastructure using VMware's product portfolio. 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.